Skip To Main Content
Yingnan Si on Muck Rack

Yingnan Si

As seen in: MDPI, BioRxiv
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yingnan

Contact Yingnan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

An Innovative Mitochondrial-targeted Gene Therapy for Cancer Treatment

|
By Kai Chen, Patrick Ernst, Seulhee Kim, Yingnan Si
| BioRxiv
Abstract Targeting cancer cell mitochondria holds great promise for cancer treatment, yet current strategies for specifically and effectively destroying cancer mitochondria in vivo are limited. Here, we introduce mLumiOpto, an innovative mitochondrial-targeted luminoptogenetics technology designed to directly disrupt the inner mitochondrial membrane (IMM) potential and induce cancer cell death.
Open in Who Shared Issue with article?

Correction: Chen et al. Targeted Extracellular Vesicles Delivered Verrucarin A to Treat Glioblastoma. Biomedicines 2022, 10, 130

|
By Kai Chen, Yingnan Si, Jia-Shiung Guan, Zhuoxin Zhou
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared View Duplicates (4) Issue with article?

Bioprocess development of antibody-drug conjugate production for cancer treatment

|
By Jianfa Ou, Yingnan Si, KahYong Goh, Norio Yasui
| PLOS
Antibody-drug conjugate (ADC) is a class of targeted cancer therapies that combine the advantages of monoclonal antibody (mAb)’s specific targeting and chemotherapy’s potent cytotoxicity. The therapeutic effect of ADC is significantly affected by its bioproduction process. This study aims to develop an effective ADC production process using anti-HER2 mAb-drug as a model therapeutic. First, a high titer (>2 g/L) of mAb was produced by Chinese hamster ovary cells from fed-batch cell culture.
Open in Who Shared Issue with article?
See all 3 articles